H.C. Wainwright analyst Oren Livnat raised his price target for Pacira Pharmaceuticals to $52 saying the company's Q2 results delivered even better operating margins and bottom-line than he expected after the preannouncement. The company is seeing its "best operational momentum in years with reimbursement about to open up," Livnat tells investors in a post-earnings research note. Further, he believes that faster Exparel adoption in early 2019, or setbacks to potential competition, could justify a materially higher valuation and make Pacira an "obvious takeout candidate." The analyst reiterates a Buy rating on the shares.